Lexicon Pharmaceuticals | LXRX - Stock


Lexicon Pharmaceuticals reported $276K in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Abbott USD 6.99B 501M Mar/2026
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
Akebia Therapeutics USD 13M 2.61M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
AstraZeneca USD 6.57B 13M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Coherus Biosciences USD 3.17M 1.12M Dec/2025
Eli Lilly USD 14.53B 785M Mar/2026
Esperion Therapeutics USD 104.21M 915K Mar/2026
Halozyme Therapeutics USD 155.47M 21.01M Mar/2026
Illumina USD 611M 47M Mar/2026
Insmed USD 132.91M 841K Mar/2026
J&J USD 14.58B 392M Mar/2026
Lexicon Pharmaceuticals USD 276K 5K Mar/2026
MacroGenics USD 9.5M 1.59M Mar/2026
MannKind USD 49.17M 13.85M Mar/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 146M 7M Mar/2026
Novartis USD 6.29B 17M Mar/2026
PTC Therapeutics USD 75.57M 4.08M Mar/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Thermo Fisher Scientific USD 5.5B 71M Mar/2026
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
United Therapeutics USD 178.3M 4.8M Mar/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025